Evidence map›Paper›PMID 38414534›Full record

ArticleJAMIA open2024

Early prediction of end-stage kidney disease using electronic health record data: a machine learning approach with a 2-year horizon.

Panayiotis Petousis, James M Wilson, Alex V Gelvezon, Shafiul Alam, Ankur Jain, Laura Prichard, David A Elashoff, Naveen Raja, Alex A T Bui

Abstract read
In one paragraph

Article in JAMIA open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Panayiotis PetousisUCLA Health Clinical and Translational Science Institute, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.ORCID https://orcid.org/0000-0002-0696-608X
James M WilsonDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.
Alex V GelvezonUCLA Health Office of Health Informatics and Analytics, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.
Shafiul AlamUCLA Health Office of Health Informatics and Analytics, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.
Ankur JainUCLA Health Office of Health Informatics and Analytics, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.
Laura PrichardUCLA Health Office of Health Informatics and Analytics, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.
David A ElashoffBiostatistics and Computational Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.
Naveen RajaUCLA Health Faculty Practice Group and the Department of Medicine, David Geffen School of Medicine at University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.
Alex A T BuiMedical & Imaging Informatics (MII) Group, Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90024-2943, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: In the United States, end-stage kidney disease (ESKD) is responsible for high mortality and significant healthcare costs, with the number of cases sharply increasing in the past 2 decades. In this study, we aimed to reduce these impacts by developing an ESKD model for predicting its occurrence in a 2-year period. Materials and Methods: We developed a machine learning (ML) pipeline to test different models for the prediction of ESKD. The electronic health record was used to capture several kidney disease-related variables. Various imputation methods, feature selection, and sampling approaches were tested. We compared the performance of multiple ML models using area under the ROC curve (AUCROC), area under the Precision-Recall curve (PR-AUC), and Brier scores for discrimination, precision, and calibration, respectively. Explainability methods were applied to the final model. Results: Our best model was a gradient-boosting machine with feature selection and imputation methods as additional components. The model exhibited an AUCROC of 0.97, a PR-AUC of 0.33, and a Brier score of 0.002 on a holdout test set. A chart review analysis by expert physicians indicated clinical utility. Discussion and Conclusion: An ESKD prediction model can identify individuals at risk for ESKD and has been successfully deployed within our health system.

Indexed as

early prediction ESKD modelelectronic health recordend-stage kidney disease (ESKD)machine learning deployment

Identifiers

PMID38414534
PMCPMC10898824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.